Primary osteosarcoma of the uterus: a report of two cases

Effah, Kofi; Hiadzi, Edem K.; Osabutey, Anita; Boateng, Alex K.; Akosa, A. B.; Anim, Jehoram T.

doi:10.4314/gmj.v55i3.10

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A review of the available literature (Table 1) showed that the previously reported patients ranged in age from 41 to 82 years, and all but 3 patients were perimenopausal or menopausal at the time of diagnosis. The clinical manifestations of most patients were vaginal bleeding and abdominal pain (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19). In our case, the patient presented with vaginal bleeding in the early stage and mainly abdominal distension in the later stage.…”

Section: Discussionmentioning

confidence: 61%

Case Report: Clinical application of immunotherapy-based combination regimen in primary osteosarcoma of the uterus

Yang

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Primary osteosarcoma of the uterus is an extremely rare pure heterologous sarcoma of the uterus. The relevant available information is limited to case reports. To date, only 31 cases of this type of cancer have been reported. Here, we report the first clinical experience with the administration of an immunotherapy-based combination regimen for multiple metastatic primary osteosarcomas of the uterus. The patient had undergone multiple treatments prior to this regimen, but her condition continued to progress. However, after 3 cycles of immunotherapy combined with targeted therapy and chemotherapy, a review showed that the disease was stable and even in partial remission. The patient has a good quality of life, and long-term survival is expected.

show abstract

Section: Discussionmentioning

confidence: 61%

Case Report: Clinical application of immunotherapy-based combination regimen in primary osteosarcoma of the uterus

Yang

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…13 The findings of this study constitute a partial report from this campaign, which provided screening to several groups of women in Ghana (total, approximately 6000), including female migrant head porters ( kayayei ), women with sickle cell disease, 14 women with diabetes, and women living in the remote Nzulezo Stilt Village. 15 The Ghanaian arm of the initiative came to an end in October 2022. The reporting of this study conforms to STROBE guidelines.…”

Section: Methodsmentioning

confidence: 99%

HPV DNA Testing and Mobile Colposcopy for Cervical Precancer Screening in HIV Positive Women: A Comparison Between Two Settings in Ghana and Recommendation for Screening

Effah,

Anthony,

Tekpor

et al. 2024

Cancer Control

View full text Add to dashboard Cite

Introduction Women living with HIV (WLHIV) have higher prevalence and persistence rates of high-risk human papillomavirus (hr-HPV) infection with a six-fold increased risk of cervical cancer. Thus, more frequent screening is recommended for WLHIV. Objectives This retrospective descriptive cross-sectional study was conducted to investigate and compare the prevalence of hr-HPV infection and abnormal findings on mobile colposcopy in two cohorts of WLHIV following cervical screening in rural and urban settings in Ghana. Methods Through the mPharma 10 000 Women Initiative, WLHIV were screened via concurrent hr-HPV DNA testing (MA-6000; Sansure Biotech Inc., Hunan, China) and visual inspection (Enhanced Visual Assessment [EVA] mobile colposcope; MobileODT, Tel Aviv, Israel) by trained nurses. The women were screened while undergoing routine outpatient reviews at HIV clinics held at the Catholic Hospital, Battor (rural setting) and Tema General Hospital (urban setting), both in Ghana. Results Two-hundred and fifty-eight WLHIV were included in the analysis (rural, n = 132; urban, n = 126). The two groups were comparable in terms of age, time since HIV diagnosis, and duration of treatment for HIV. The hr-HPV prevalence rates were 53.7% (95% CI, 45.3–62.3) and 48.4% (95% CI, 39.7–57.1) among WLHIV screened in the rural vs urban settings ( p-value = .388). Abnormal colposcopy findings were found in 8.5% (95% CI, 5.1–11.9) of the WLHIV, with no significant difference in detection rates between the two settings ( p-value = .221). Three (13.6%) of 22 women who showed abnormal colposcopic findings underwent loop electrosurgical excision procedure (LEEP), leaving 19/22 women from both rural and urban areas with pending treatment/follow-up results, which demonstrates the difficulty faced in reaching early diagnosis and treatment, regardless of their area of residence. Histopathology following LEEP revealed CIN III in 2 WLHIV (urban setting, both hr-HPV negative) and CIN I in 1 woman in the rural setting (hr-HPV positive). Conclusions There is a high prevalence of hr-HPV among WLHIV in both rural and urban settings in this study in Ghana. Concurrent HPV DNA testing with a visual inspection method (colposcopy/VIA) reduces loss to follow-up compared to performing HPV DNA testing as a standalone test and recalling hr-HPV positive women for follow up with a visual inspection method. Concurrent HPV DNA testing and a visual inspection method may also pick up precancerous cervical lesions that are hr-HPV negative and may be missed if HPV DNA testing is performed alone.

show abstract

Primary osteosarcoma of the uterus: a report of two cases

Cited by 2 publications

References 15 publications

Case Report: Clinical application of immunotherapy-based combination regimen in primary osteosarcoma of the uterus

Case Report: Clinical application of immunotherapy-based combination regimen in primary osteosarcoma of the uterus

HPV DNA Testing and Mobile Colposcopy for Cervical Precancer Screening in HIV Positive Women: A Comparison Between Two Settings in Ghana and Recommendation for Screening

Contact Info

Product

Resources

About